3 August 2018 - - US-based specialty access solutions provider Tanner Pharma Group has signed a distribution agreement with inhaled therapeutic products specialist MannKind Corp., the company said.

MannKind is a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

The agreement names Tanner as a distributor of Afrezza (insulin human) Inhalation Powder in areas outside of the United States where the product is not yet registered. Afrezza is a rapid-acting, inhaled insulin for Type 1 and Type 2 diabetes.

The ex-US distribution will be managed by TannerGAP, Inc., a wholly owned subsidiary of Tanner Pharma Group.

TannerGAP offers turnkey global access solutions for the distribution of products from markets of supply to markets of demand.

For over 15 years, Tanner Pharma Group has provided highly specialised pharmaceutical services to its partners.

Companies partner with Tanner Pharma to license and commercialise their products in challenging international markets, develop and manage their Global Access Programs, and source comparator drugs for clinical trials and bioanalysis.

MannKind Corp. (NASDAQ: MNKD) focuses on the development and commercialisation of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

The company is currently commercialising Afrezza (insulin human) Inhalation Powder, the company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The company also employs field sales and medical representatives across the US.